Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 8/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037130 | 1.00 | MBNL1 (0.47) | MBNL1DHODHHTR5AKMOCSNK2A2 | |
| SCHEMBL30037588 | 0.90 | DHODH (0.41) | MBNL1DHODHHTR5AKMOCSNK2A2 | |
| SCHEMBL25551942 | 0.89 | KMO (0.42) | MBNL1DHODHKMO | |
| SCHEMBL30037152 | 0.89 | KMO (0.42) | MBNL1DHODHKMO | |
| SCHEMBL30036500 | 0.87 | HTR5A (0.48) | MBNL1DHODHHTR5ANPC1RAB9A | |
| SCHEMBL25552011 | 0.85 | MBNL1 (0.43) | MBNL1DHODHHTR5ANPC1RAB9A | |
| SCHEMBL30036976 | 0.85 | MBNL1 (0.43) | MBNL1DHODHHTR5ANPC1RAB9A | |
| SCHEMBL25244771 | 0.83 | DHODH (0.47) | DHODHKMOCSNK2A2CSNK2B | |
| SCHEMBL32680061 | 0.83 | DHODH (0.44) | DHODHKMOPDK1 | |
| SCHEMBL25208397 | 0.83 | DHODH (0.44) | DHODHKMOPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| CN-115515940-A | Inhibitors of receptor interacting protein kinase I for the treatment of disease | 德州大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | MBNL1 1407/4885DHODH 4384/4885HTR5A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.